Muhammad Al Anas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Al Anas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dedy Hermansyah
Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
3 shared publications Endi Taris Pasaribu
2 shared publicationsEdwin Saleh Siregar
Surgery, University of North Sumatra, Medan, Indonesia
1 shared publicationKania Haura Chalisaturahmi
University of North Sumatra,Medan,Faculty of Medicine,Department of Surgery,Indonesia
1 shared publicationKarina Sugih Arto
University of North Sumatra,Medan,Faculty of Mediicne,Indonesia
1 shared publicationMutiara Baitina
University of North Sumatra,Medan,Faculty of Medicine,Department of Surgery,Indonesia
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Chemotherapy-Induced Upregulation of X-Linked Inhibitor of Apoptosis Protein Is Associated with Survival After Chemotherapy in Triple-Negative Breast Cancer
Background and Objectives: Triple-negative breast cancer remains difficult to treat because endocrine and HER2-directed therapies are not applicable, leaving cytotoxic chemotherapy as an important systemic treatment. We examined whether chemotherapy exposure was accompanied by XIAP upregulation in an MDA-MB-231 model and whether XIAP expression was associated with the surviving cell fraction.Methods: MDA-MB-231 cells obtained from ATCC were exposed to graded concentrations of paclitaxel and doxorubicin. Cytotoxicity was assessed by MTT assay. A combined paclitaxel–doxorubicin condition was evaluated for surviving cell fraction. XIAP messenger RNA was quantified by reverse-transcription real-time polymerase chain reaction using GAPDH for normalization and the 2−ΔΔCt method. An exploratory Eta coefficient was calculated to describe the association between XIAP expression and chemotherapy survival.Results: Paclitaxel and doxorubicin produced concentration-dependent inhibition. Estimated IC50 values were 0.423 µg/mL and 1.74 µg/mL, respectively. Combined treatment yielded 580,000 viable cells versus 2,000,000 in the untreated control, corresponding to a surviving fraction of 0.29. Relative XIAP expression in the treated sample was 178.53-fold that of the untreated control. The exploratory Eta coefficient was 0.748.Conclusions: Chemotherapy exposure was accompanied by a marked increase in XIAP transcript abundance in the surviving cell population. The finding supports XIAP as a biologically plausible marker of chemotherapy tolerance, but causality cannot be established from the present design. Independent biological replicates, protein-level validation, apoptosis assays, and XIAP perturbation are required before therapeutic conclusions can be drawn.
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessChemotherapy-Induced Upregulation of X-Linked Inhibitor of Apoptosis Protein Is Associated with Survival After Chemotherapy in Triple-Negative Breast Cancer
Background and Objectives: Triple-negative breast cancer remains difficult to treat because endocrine and HER2-directed therapies are not applicable, leaving cytotoxic chemotherapy as an important systemic treatment. We examined whether chemotherapy exposure was accompanied by XIAP upregulation in an MDA-MB-231 model and whether XIAP expression was associated with the surviving cell fraction.Methods: MDA-MB-231 cells obtained from ATCC were exposed to graded concentrations of paclitaxel and doxorubicin. Cytotoxicity was assessed by MTT assay. A combined paclitaxel–doxorubicin condition was evaluated for surviving cell fraction. XIAP messenger RNA was quantified by reverse-transcription real-time polymerase chain reaction using GAPDH for normalization and the 2−ΔΔCt method. An exploratory Eta coefficient was calculated to describe the association between XIAP expression and chemotherapy survival.Results: Paclitaxel and doxorubicin produced concentration-dependent inhibition. Estimated IC50 values were 0.423 µg/mL and 1.74 µg/mL, respectively. Combined treatment yielded 580,000 viable cells versus 2,000,000 in the untreated control, corresponding to a surviving fraction of 0.29. Relative XIAP expression in the treated sample was 178.53-fold that of the untreated control. The exploratory Eta coefficient was 0.748.Conclusions: Chemotherapy exposure was accompanied by a marked increase in XIAP transcript abundance in the surviving cell population. The finding supports XIAP as a biologically plausible marker of chemotherapy tolerance, but causality cannot be established from the present design. Independent biological replicates, protein-level validation, apoptosis assays, and XIAP perturbation are required before therapeutic conclusions can be drawn.
- Open Access
- 27 February 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (1) , 80-84
Elevated neutrophil-to-lymphocyte ratio predicts poorer histopathological differentiation in colorectal cancer: a study from a Southeast Asian Tertiary Hospital
Aim of this study was to evaluate the correlation between pre-treatment NLR and histopathological differentiation in colorectal cancer, and to assess the diagnostic accuracy of NLR as a predictive biomarker. Methods A retrospective study was conducted at Adam Malik Haji Center General Hospital Medan, North Sumatera. Medical records of 45 colorectal cancer patients treated between January and December 2024 were reviewed. Pre-treatment NLR values were calculated from peripheral blood counts. Receiver Operating Characteristic (ROC) curve analysis was performed to determine diagnostic performance, and correlation analysis was used to assess the relationship between NLR and tumour grade. Results The mean NLR was 6.33±4.92. ROC analysis yielded an area under the curve (AUC) of 0.874, indicating excellent diagnostic ability. An NLR cutoff value of 6.25 provided a sensitivity of 87.5% and specificity of 72.5% for predicting poor histopathological differentiation. A moderate positive correlation (r=0.612; p<0.001) was found between higher NLR values and poorer differentiation. Conclusion Pre-treatment NLR correlated with histopathological grade and showed promise as a simple, non-invasive biomarker for assessing tumour aggressiveness in colorectal cancer.
- 27 February 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (1) , 80-84
Open AccessElevated neutrophil-to-lymphocyte ratio predicts poorer histopathological differentiation in colorectal cancer: a study from a Southeast Asian Tertiary Hospital
Aim of this study was to evaluate the correlation between pre-treatment NLR and histopathological differentiation in colorectal cancer, and to assess the diagnostic accuracy of NLR as a predictive biomarker. Methods A retrospective study was conducted at Adam Malik Haji Center General Hospital Medan, North Sumatera. Medical records of 45 colorectal cancer patients treated between January and December 2024 were reviewed. Pre-treatment NLR values were calculated from peripheral blood counts. Receiver Operating Characteristic (ROC) curve analysis was performed to determine diagnostic performance, and correlation analysis was used to assess the relationship between NLR and tumour grade. Results The mean NLR was 6.33±4.92. ROC analysis yielded an area under the curve (AUC) of 0.874, indicating excellent diagnostic ability. An NLR cutoff value of 6.25 provided a sensitivity of 87.5% and specificity of 72.5% for predicting poor histopathological differentiation. A moderate positive correlation (r=0.612; p<0.001) was found between higher NLR values and poorer differentiation. Conclusion Pre-treatment NLR correlated with histopathological grade and showed promise as a simple, non-invasive biomarker for assessing tumour aggressiveness in colorectal cancer.
- Open Access
- 25 August 2025
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 22 (2) , 268-272
Correlation of Ki67 expression with estrogen receptor (ER) and progesterone receptor (PR) status in breast cancer
Aim To determine whether Ki67 can be predicted through its correlation with the estrogen receptor (ER) and progesterone receptor (PR), to identify breast cancer subtypes and evaluate cell proliferation level and prognosis. Methods Patient clinical data were collected from medical records and pathology laboratory reports at Teaching Hospital, Faculty of Medicine, Universitas Sumatera Utara. Ki67 expression, as a proliferation marker, was measured and detected using immunohistochemistry (IHC). Ki67 data were categorized into two groups: 20% (high proliferation). Statistical analysis was conducted by calculating the frequency distribution and percentage of receptor status and using the χ2 test. Results The study revealed an inverse relationship between ER/PR status and Ki67 (<0.001). Low Ki67 levels were generally associated with positive ER/PR status, while high Ki67 levels showed increased frequency in ER/PR- negative cases. Conclusion: Ki67 expression can be determined based on the frequency of ER/PR status; however, these markers have distinct roles in the management of breast cancer patients.
- 25 August 2025
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 22 (2) , 268-272
Open AccessCorrelation of Ki67 expression with estrogen receptor (ER) and progesterone receptor (PR) status in breast cancer
Aim To determine whether Ki67 can be predicted through its correlation with the estrogen receptor (ER) and progesterone receptor (PR), to identify breast cancer subtypes and evaluate cell proliferation level and prognosis. Methods Patient clinical data were collected from medical records and pathology laboratory reports at Teaching Hospital, Faculty of Medicine, Universitas Sumatera Utara. Ki67 expression, as a proliferation marker, was measured and detected using immunohistochemistry (IHC). Ki67 data were categorized into two groups: 20% (high proliferation). Statistical analysis was conducted by calculating the frequency distribution and percentage of receptor status and using the χ2 test. Results The study revealed an inverse relationship between ER/PR status and Ki67 (<0.001). Low Ki67 levels were generally associated with positive ER/PR status, while high Ki67 levels showed increased frequency in ER/PR- negative cases. Conclusion: Ki67 expression can be determined based on the frequency of ER/PR status; however, these markers have distinct roles in the management of breast cancer patients.